As of June 2, 2025, Theseus Pharmaceuticals Inc (THRX) reports a Current Ratio of 18.21.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Theseus Pharmaceuticals Inc's Current Ratio
Over recent years, Theseus Pharmaceuticals Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2022-12-31 | 18.21 |
| 2021-12-31 | 67.03 |
| 2020-12-31 | 5.38 |
| 2019-12-31 | 2.33 |
This slight upward trend highlights how Theseus Pharmaceuticals Inc manages its short-term assets and liabilities over time.
Comparing Theseus Pharmaceuticals Inc's Current Ratio to Peers
To better understand Theseus Pharmaceuticals Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Theseus Pharmaceuticals Inc (THRX) | 18.21 |
| Catalent Inc (CTLT) | 2.52 |
| Elanco Animal Health Inc (ELAN) | 2.44 |
| Zoetis Inc (ZTS) | 1.75 |
| Viatris Inc (VTRS) | 1.65 |
| Royalty Pharma PLC (RPRX) | 1.44 |
Compared to its competitors, Theseus Pharmaceuticals Inc's Current Ratio is higher than all peers, indicating strong short-term financial flexibility but potentially excess cash that could be invested.